Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

	d 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/	09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12
Name o	of entity	
	TA THERAPEUTICS LIMITED	
ABN		
	4 037 372	
TAT (:	1	
we (t	the entity) give ASX the following	ig information.
	1 - All issues ast complete the relevant sections (attach s	heets if there is not enough space).
1	⁺ Class of ⁺ securities issued or to be issued	Fully paid ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	500,000
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares
4	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?	Yes – the shares issued rank equally with existing fully paid ordinary shares.
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend,	

distribution or interest payment

⁺ See chapter 19 for defined terms.

5	Issue price or consideration	\$1.00 per fully paid ordinary share.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of unlisted 17 July 2020 options.
ба	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the</i> ⁺ securities the	Yes
	subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	15 November 2018
6c	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of securities issued under an exception in rule 7.2	500,000 fully paid ordinary shares – exception 4.
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 15,125,257 7.1A 10,283,505

⁺ See chapter 19 for defined terms.

7	Dates of entering *securities into uncertificated holdings or despatch of certificates	18 September 2019)
		Nameleon	+Class
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in section 2 if applicable)	Number 102,835,053	+Class Fully paid ordinary shares
		Number	+Class
9	Number and +class of all +securities not quoted on ASX (<i>including</i> the securities in section 2 if applicable)	1,340,557	Unlisted options exercise price \$1.00, expiring 17 July 2020.
		500,000	Unlisted options exercise price \$1.022, expiring 17 November 2019.
		2,000,000	Unlisted options exercise price \$1.50 expiring 17 November 2019.
		100,000	Unlisted options exercise price \$0.88 expiring 4 August 2020.
		1,425,000	Unlisted options exercise price \$1.75 expiring 16 May 2022 (subject to vesting conditions).
		300,000	Unlisted options exercise price \$2.11 expiring 16 May 2024 (subject to vesting conditions).
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part 2	2 - Bonus issue or pro ra	ta issue	
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the *securities will be offered	N/A	

⁺ See chapter 19 for defined terms.

14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
	Cross reference, rule 1.1.	
19	Closing date for receipt of acceptances or renunciations	N/A
• •		
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A

⁺ See chapter 19 for defined terms.

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Despatch date	N/A
Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities		
34	Type of securities (tick one)	
(a)	X Securities described in Part 1	
(b)	I =	of the escrowed period, partly paid securities that become fully paid, employee ends, securities issued on expiry or conversion of convertible securities
Entities that have ticked box 34(a)		
Additional securities forming a new class of securities		

Tick to indicate you are providing the information or documents

⁺ See chapter 19 for defined terms.

35	If the *securities are *equity additional *securities, and the those holders		_
36	If the *securities are *equity *securities setting out the numb 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
37	A copy of any trust deed for the	e additional *securities	
Entitie	s that have ticked box 34(b)		
38	Number of securities for which ⁺ quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)	Number	Giass

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers

for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at the
 time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: 18 September 2019 (Director/Company secretary)

Print name: Peter Webse

== == == ==

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	95,658,624	4
 Add the following: Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	5,100,000 12,500 155,000 218,929 350,000 50,000 150,000 50,000 50,000 50,000 50,000 50,000 50,000	fully paid ordinary shares issued on 25 September 2018 – Exception 4 fully paid ordinary shares issued on 4 February 2019 – Exception 4 fully paid ordinary shares issued on 11 February 2019 – Exception 4 fully paid ordinary shares issued on 18 February 2019 – Exception 4 fully paid ordinary shares issued on 18 February 2019 – Exception 4 fully paid ordinary shares issued on 22 February 2019 – Exception 4 fully paid ordinary shares issued on 13 March 2019 – Exception 4 fully paid ordinary shares issued on 20 March 2019 – Exception 4 fully paid ordinary shares issued on 7 May 2019 – Exception 4 fully paid ordinary shares issued on 2 August 2019 – Exception 4 fully paid ordinary shares issued on 15 August 2019 – Exception 4 fully paid ordinary shares issued on 27 August 2019 – Exception 4 fully paid ordinary shares issued on 3 September 2019 – Exception 4 fully paid ordinary shares issued on 18 September 2019 – Exception 4 fully paid ordinary shares issued on 18 September 2019 – Exception 4
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	-	
"A"	102,835,0	53

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	15,425,257	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	300,000 unlisted options 17 May 2019	
 Under an exception in rule 7.2 		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	300,000	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	15,425,257	
Note: number must be same as shown in Step 2		
Subtract "C"	300,000	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	15,125,257	
	[Note: this is the remaining placement capacity under rule 7.1]	

Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	102,835,053	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	10,283,505	
Step 3: Calculate "E", the amount 7.1A that has already been used	of placement capacity under rule	
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items	-	
Step 4: Subtract "E" from ["A" x ' placement capacity under rule 7.1		
"A" x 0.10	10,283,505	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	10,283,505	
	Note: this is the remaining placement capacity under rule 7.1A	

⁺ See chapter 19 for defined terms. 01/08/2012